High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

PURPOSE: Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets. METHODS: We assembled...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Berry, Donald A., Ueno, Naoto T., Johnson, Marcella M., Lei, Xiudong, Caputo, Jean, Rodenhuis, Sjoerd, Peters, William P., Leonard, Robert C., Barlow, William E., Tallman, Martin S., Bergh, Jonas, Nitz, Ulrike A., Gianni, Alessandro M., Basser, Russell L., Zander, Axel R., Coombes, R. Charles, Roché, Henri, Tokuda, Yutaka, de Vries, Elisabeth G.E., Hortobagyi, Gabriel N., Crown, John P., Pedrazzoli, Paolo, Bregni, Marco, Demirer, Taner
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2011
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322115/
https://ncbi.nlm.nih.gov/pubmed/21768471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5910
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak